ReviewAnnual review of biomedical engineering2021
In Situ Programming of CAR T Cells.
Review in Annual review of biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Circadian engineering of in vivo CAR T cell therapy for precision oncology.NPJ precision oncology · 2026Review
- Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.Cancer research · 2026Review
- Review
- Plying potency assays for immunotherapy of solid tumors.Frontiers in immunology · 2026Review
- CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases.Frontiers in immunology · 2026Review
- B cell targeted CAR-T therapy for autoimmune diseases.Frontiers of medicine · 2025Review
- Review
- In vivo CAR engineering for immunotherapy.Nature reviews. Immunology · 2025Review
- Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases.Molecular therapy. Methods & clinical development · 2025Review
- Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles.Nature communications · 2025Article
- Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025Review
- Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer.Experimental hematology & oncology · 2025Article
- CAR-T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View.Cancer medicine · 2025Review
- Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond.Frontiers in immunology · 2025Review
- Universal CAR cell therapy: Challenges and expanding applications.Translational oncology · 2025Review
- CAR-T cell therapy: Advances in digestive system malignant tumors.Molecular therapy. Oncology · 2024Review
- Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024Review
- Implantable CAR T cell factories enhance solid tumor treatment.Biomaterials · 2024Article
- Steering the course of CAR T cell therapy with lipid nanoparticles.Journal of nanobiotechnology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Gene therapy makes it possible to engineer chimeric antigen receptors (CARs) to create T cells that target specific diseases. However, current approaches require elaborate and expensive protocols to manufacture engineered T cells ex vivo, putting this therapy beyond the reach of many patients who might benefit. A solution could be to program T cells in vivo. Here, we evaluate the clinical need for in situ CAR T cell programming, compare competing technologies, review current progress, and provide a perspective on the long-term impact of this emerging and rapidly flourishing biotechnology field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.